COMBS ANDREW (EVP, Head of Chemistry) purchased 20.1% of their position (63.08K shares) of PRELUDE THERAPEUTICS INC on the open market
Open‑market purchase worth $85.5K — a significant purchase. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 12/26/2024ACC: 0001562180-24-008565
Officer· EVP, Head of Chemistry
Since Sep 2020
+63.08K
Net shares
Net buyer
$85.5K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
63.08K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+3.08K
Price / share
$1.15
Trade value
$3.54K
% of position
1.0%
12/20/2024
314.55K→317.62K
Common Stock
Direct
Shares
+60K
Price / share
$1.37
Trade value
$82K
% of position
18.9%
12/23/2024
317.62K→377.62K
Total
Net shares
+63.08K
Net value
$85.54K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/20/2024 | P · Purchase | +3.08K | $1.15 | $3.54K | 1.0% | 314.55K | 317.62K |
| Common Stock Direct | 12/23/2024 | P · Purchase | +60K | $1.37 | $82K | 18.9% | 317.62K | 377.62K |
| Total | +63.08K | $85.54K | ||||||
Derivative Transactions0
No derivative transactions reported